

MD7009/MD7259 Clinical Presentation & Management in Diabetes: Glycaemic Control, New & Novel Therapies

View Online



[1]

Richard I. G. Holt, , Clive Cockram, , Allan Flyvbjerg, , and Barry J. Goldstein, Textbook of Diabetes. John Wiley, 2016 [Online]. Available: <https://ebookcentral-proquest-com.ezproxy4.lib.le.ac.uk/lib/leicester/reader.action?docID=4769056>

[2]

'Type 2 diabetes in adults: management | Guidance and guidelines | NICE' [Online]. Available: <https://www.nice.org.uk/guidance/ng28>

[3]

'Resources and tools'. [Online]. Available: <http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/78:global-guideline-for-managing-older-people-with-type-2-diabetes.html>

[4]

'Resources and tools'. [Online]. Available: <http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/79:global-guideline-for-type-2-diabetes.html>

[5]

'Resources and tools'. [Online]. Available: <http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/80:the-global-idf-ispad-guidelines-for-diabetes-in-childhood-and-adolescence.html>

[6]

W. Crasto, J. Jarvis, and M. J. Davies, Handbook of insulin therapies. Switzerland: Adis, 2016 [Online]. Available:

http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745

[7]

Anthony H. Barnett, Jenny Grice, New Mechanisms in Glucose Control. BMJ Books; 1 edition, 2013 [Online]. Available:

<http://ezproxy.lib.le.ac.uk/login?url=http://lib.myilibrary.com?id=478133>

[8]

'WHO 2011 Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus'.

[Online]. Available: http://www.who.int/diabetes/publications/diagnosis_diabetes2011/en/

[9]

M. A. Atkinson, 'The Pathogenesis and Natural History of Type 1 Diabetes', Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 11, pp. a007641–a007641, Nov. 2012, doi: 10.1101/cshperspect.a007641.

[10]

V. T. Samuel and G. I. Shulman, 'Intergrating Mechanisms for Insulin Resistance: Common Threads and Missing Links', Cell, vol. 148, no. 5, pp. 852–871, Mar. 2012, doi: 10.1016/j.cell.2012.02.017.

[11]

Beverley M Shields, 'Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature', BMJ Open, vol. 5, no. 11, 2015, doi: 10.1136/bmjopen-2015-009088. [Online]. Available:

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636628/?report=classic>

[12]

F. Zaccardi, D. R. Webb, T. Yates, and M. J. Davies, 'Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective', *Postgraduate Medical Journal*, vol. 92, no. 1084, pp. 63–69, Feb. 2016, doi: 10.1136/postgradmedj-2015-133281.

[13]

A. G. Jones and A. T. Hattersley, 'The clinical utility of C-peptide measurement in the care of patients with diabetes', *Diabetic Medicine*, vol. 30, no. 7, pp. 803–817, Jul. 2013, doi: 10.1111/dme.12159.

[14]

B. T. Srinivasan, J. Jarvis, K. Khunti, and M. J. Davies, 'Recent advances in the management of type 2 diabetes mellitus: a review', *Postgraduate Medical Journal*, vol. 84, no. 996, pp. 524–531, Oct. 2008, doi: 10.1136/pgmj.2008.067918.

[15]

K. C. Copeland et al., 'Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents', *PEDIATRICS*, vol. 131, no. 2, pp. 364–382, Feb. 2013, doi: 10.1542/peds.2012-3494.

[16]

Celia G. Walker, 'Modelling the Interplay between Lifestyle Factors and Genetic Predisposition on Markers of Type 2 Diabetes Mellitus Risk', *PLoS ONE*, vol. 10, no. 7, 2015, doi: 10.1371/journal.pone.0131681. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496090/>

[17]

S. Chatterjee and M. Davies, 'Type 2 diabetes: recent advances in diagnosis and management', *Prescriber*, vol. 26, no. 10, pp. 15–21, May 2015, doi: 10.1002/psb.1355.

[18]

F. Ismail-Beigi, 'Glycemic Management of Type 2 Diabetes Mellitus', *New England Journal of Medicine*, vol. 366, no. 14, pp. 1319–1327, Apr. 2012, doi: 10.1056/NEJMcp1013127.

[19]

D. M. Nathan et al., 'Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes', *Diabetes Care*, vol. 29, no. 8, pp. 1963–1972, Aug. 2006, doi: 10.2337/dc06-9912.

[20]

B. T. Srinivasan and M. Davies, 'Glycaemic management of type 2 diabetes', *Medicine*, vol. 42, no. 12, pp. 711–717, Dec. 2014, doi: 10.1016/j.mpmed.2014.09.011.

[21]

S M Attard, 'Implications of iron deficiency/anemia on the classification of diabetes using HbA1c', *Nutrition & Diabetes*, vol. 5, no. 6, 2015, doi: doi: 10.1038/nutd.2015.16. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491857/>

[22]

S. S. Schwartz, S. Epstein, B. E. Corkey, S. F. A. Grant, J. R. Gavin, and R. B. Aguilar, 'The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β -Cell-Centric Classification Schema', *Diabetes Care*, vol. 39, no. 2, pp. 179–186, Feb. 2016, doi: 10.2337/dc15-1585.

[23]

C. J. Nolan, N. B. Ruderman, S. E. Kahn, O. Pedersen, and M. Prentki, 'Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes', *Diabetes*, vol. 64, no. 3, pp. 673–686, Mar. 2015, doi: 10.2337/db14-0694.

[24]

C. V. Rizos, A. Kei, and M. S. Elisaf, 'The current role of thiazolidinediones in diabetes

management', *Archives of Toxicology*, vol. 90, no. 8, pp. 1861–1881, Aug. 2016, doi: 10.1007/s00204-016-1737-4.

[25]

S. E. Nissen and K. Wolski, 'Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes', *New England Journal of Medicine*, vol. 356, no. 24, pp. 2457–2471, Jun. 2007, doi: 10.1056/NEJMoa072761.

[26]

'Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes'. 4AD [Online]. Available: <https://www.youtube.com/watch?v=AhhWTmEFuag>

[27]

'[ARCHIVED CONTENT] Medicines management: Everybody's business : Department of Health - Publications and statistics'. [Online]. Available: http://webarchive.nationalarchives.gov.uk/20080205142458/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_082200

[28]

A. F. Vloemans et al., 'Keeping safe. Continuous glucose monitoring (CGM) in persons with Type 1 diabetes and impaired awareness of hypoglycaemia: a qualitative study', *Diabetic Medicine*, vol. 34, no. 10, pp. 1470–1476, Oct. 2017, doi: 10.1111/dme.13429.

[29]

S. Sivasubramaniyam, S. A. Amiel, and P. Choudhary, 'Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range', *Diabetic Medicine*, vol. 34, no. 10, pp. 1456–1460, Oct. 2017, doi: 10.1111/dme.13438.

[30]

W. Crasto, J. Jarvis, and M. J. Davies, *Handbook of insulin therapies*. Switzerland: Adis, 2016 [Online]. Available: <http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&pack>

age_service_id=5664687440002746&institutionId=2746&customerId=2745

[31]

S. E. Inzucchi et al., 'Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes', *Diabetes Care*, vol. 38, no. 1, pp. 140–149, Jan. 2015, doi: 10.2337/dc14-2441.

[32]

B. Ryder et al., 'ABCD position statement on GLP-1 based therapies and pancreatic damage', *Practical Diabetes*, vol. 30, no. 9, pp. 388–391, Nov. 2013, doi: 10.1002/pdi.1816.

[33]

A. J. Garber et al., 'Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial', *The Lancet*, vol. 379, no. 9825, pp. 1498–1507, Apr. 2012, doi: 10.1016/S0140-6736(12)60205-0.

[34]

S. Gururaj Setty, W. Crasto, J. Jarvis, K. Khunti, and M. J. Davies, 'New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes', *Postgraduate Medical Journal*, vol. 92, no. 1085, pp. 152–164, Mar. 2016, doi: 10.1136/postgradmedj-2015-133716.

[35]

Z. Z. Htike, F. Zaccardi, S. Chatterjee, K. Khunti, and M. J. Davies, 'Glucagon like peptide-1 receptor agonist (GLP-1RA) therapy in management of type 2 diabetes: choosing the right agent for individualised care', *British Journal of Diabetes*, vol. 16, no. 3, Sep. 2016, doi: 10.15277/bjd.2016.091.

[36]

M. J. Davies and S. Chatterjee, 'Trial watch: Insulin initiation for type 2 diabetes mellitus in primary care', *Nature Reviews Endocrinology*, vol. 13, no. 6, pp. 317–318, Apr. 2017, doi: 10.1038/nrendo.2017.41.

[37]

S. C. L. Gough, S. Harris, V. Woo, and M. Davies, 'Insulin degludec: overview of a novel ultra long-acting basal insulin', *Diabetes, Obesity and Metabolism*, vol. 15, no. 4, pp. 301–309, Apr. 2013, doi: 10.1111/dom.12052.

[38]

S. G. Ashwell et al., 'Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes', *Diabetic Medicine*, vol. 23, no. 3, pp. 285–292, Mar. 2006, doi: 10.1111/j.1464-5491.2005.01781.x.

[39]

R. G. Bretzel, U. Nuber, W. Landgraf, D. R. Owens, C. Bradley, and T. Linn, 'Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial', *The Lancet*, vol. 371, no. 9618, pp. 1073–1084, Mar. 2008, doi: 10.1016/S0140-6736(08)60485-7.

[40]

M. M. Funnell, 'Overcoming Barriers to the Initiation of Insulin Therapy', *Clinical Diabetes*, vol. 25, no. 1, pp. 36–38, Jan. 2007, doi: 10.2337/diaclin.25.1.36.

[41]

A. J. Garber et al., 'Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study)', *Diabetes, Obesity and Metabolism*, vol. 8, no. 1, pp. 58–66, Jan. 2006, doi: 10.1111/j.1463-1326.2005.00563.x.

[42]

S. C. L. Gough, 'A review of human and analogue insulin trials', *Diabetes Research and Clinical Practice*, vol. 77, no. 1, pp. 1–15, Jul. 2007, doi: 10.1016/j.diabres.2006.10.015.

[43]

A. J. Garber, R. Ligthelm, J. S. Christiansen, and A. Liebl, 'Premixed insulin treatment for type 2 diabetes: analogue or human?', *Diabetes, Obesity and Metabolism*, vol. 9, no. 5, pp. 630–639, Sep. 2007, doi: 10.1111/j.1463-1326.2006.00654.x.

[44]

S. R. Heller et al., 'Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes', *Diabetic Medicine*, vol. 21, no. 7, pp. 769–775, Jul. 2004, doi: 10.1111/j.1464-5491.2004.01244.x.

[45]

K. Hermansen, M. Davies, T. Derezinski, G. Martinez Ravn, P. Clauson, and P. Home, 'A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes', *Diabetes Care*, vol. 29, no. 6, pp. 1269–1274, Jun. 2006, doi: 10.2337/dc05-1365.

[46]

R. R. Holman et al., 'Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes', *New England Journal of Medicine*, vol. 357, no. 17, pp. 1716–1730, Oct. 2007, doi: 10.1056/NEJMoa075392.

[47]

R. R. Holman and R. C. Turner, 'A Practical Guide to Basal and Prandial Insulin Therapy', *Diabetic Medicine*, vol. 2, no. 1, pp. 45–53, Jan. 1985, doi: 10.1111/j.1464-5491.1985.tb00592.x.

[48]

K. Horvath et al., 'Long-acting insulin analogues versus NPH insulin (human isophane

insulin) for type 2 diabetes mellitus', in Cochrane Database of Systematic Reviews, Chichester, UK: John Wiley & Sons, Ltd, 1996 [Online]. Available: <http://doi.wiley.com/10.1002/14651858.CD005613.pub3>

[49]

M. Marre et al., 'Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)', *Diabetic Medicine*, vol. 26, no. 3, pp. 268–278, Mar. 2009, doi: 10.1111/j.1464-5491.2009.02666.x.

[50]

L. A. Young and J. B. Buse, 'GLP-1 receptor agonists and basal insulin in type 2 diabetes', *The Lancet*, vol. 384, no. 9961, pp. 2180–2181, Dec. 2014, doi: 10.1016/S0140-6736(14)61409-4.

[51]

M. Diamant et al., 'Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial', *The Lancet*, vol. 375, no. 9733, pp. 2234–2243, Jun. 2010, doi: 10.1016/S0140-6736(10)60406-0.

[52]

S. Gururaj Setty, W. Crasto, J. Jarvis, K. Khunti, and M. J. Davies, 'New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes', *Postgraduate Medical Journal*, vol. 92, no. 1085, pp. 152–164, Mar. 2016, doi: 10.1136/postgradmedj-2015-133716.

[53]

J. Rosenstock et al., 'Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)', *Diabetes Care*, vol. 36, no. 10, pp. 2945–2951, Oct. 2013, doi: 10.2337/dc12-2709.

[54]

M. Evans, P. M. Schumm-Draeger, J. Vora, and A. B. King, 'A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations', *Diabetes, Obesity and Metabolism*, vol. 13, no. 8, pp. 677–684, Aug. 2011, doi: 10.1111/j.1463-1326.2011.01395.x.

[55]

P. D. Home, 'The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences', *Diabetes, Obesity and Metabolism*, vol. 14, no. 9, pp. 780–788, Sep. 2012, doi: 10.1111/j.1463-1326.2012.01580.x.

[56]

B. Richter and G. Neises, "'Human" insulin versus animal insulin in people with diabetes mellitus', in *Cochrane Database of Systematic Reviews*, Chichester, UK: John Wiley & Sons, Ltd, 1996 [Online]. Available: <http://doi.wiley.com/10.1002/14651858.CD003816.pub2>

[57]

S. G. Swinnen, A. C. Simon, F. Holleman, J. B. Hoekstra, and J. H. DeVries, 'Insulin detemir versus insulin glargine for type 2 diabetes mellitus', in *Cochrane Database of Systematic Reviews*, Chichester, UK: John Wiley & Sons, Ltd, 1996 [Online]. Available: <http://doi.wiley.com/10.1002/14651858.CD006383.pub2>

[58]

H. Yki-Järvinen et al., 'Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study', *Diabetologia*, vol. 49, no. 3, pp. 442–451, Mar. 2006, doi: 10.1007/s00125-005-0132-0.

[59]

B. Zinman et al., 'Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial', *The Lancet*, vol. 377, no. 9769, pp. 924–931, Mar. 2011, doi: 10.1016/S0140-6736(10)62305-7.

[60]

K. Horvath et al., 'Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus', in *Cochrane Database of Systematic Reviews*, Chichester, UK: John Wiley & Sons, Ltd, 1996 [Online]. Available: <http://doi.wiley.com/10.1002/14651858.CD005613.pub3>

[61]

J. Rosenstock, M. Davies, P. D. Home, J. Larsen, C. Koenen, and G. Schernthaner, 'A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes', *Diabetologia*, vol. 51, no. 3, pp. 408–416, Mar. 2008, doi: 10.1007/s00125-007-0911-x.

[62]

P. Raskin et al., 'Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs', *Diabetes Care*, vol. 28, no. 2, pp. 260–265, Feb. 2005, doi: 10.2337/diacare.28.2.260.

[63]

M. Davies, F. Storms, S. Shutler, M. Bianchi-Biscay, and R. Gomis, 'Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine', *Diabetes Care*, vol. 28, no. 6, pp. 1282–1288, Jun. 2005, doi: 10.2337/diacare.28.6.1282.

[64]

Z. Z. Htike, F. Zaccardi, D. Papamargaritis, D. R. Webb, K. Khunti, and M. J. Davies, 'Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis', *Diabetes, Obesity and Metabolism*, vol. 19, no. 4, pp. 524–536, Apr. 2017, doi: 10.1111/dom.12849.

[65]

Z. Z. Htike, F. Zaccardi, D. Papamargaritis, D. R. Webb, K. Khunti, and M. J. Davies, 'Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis', *Diabetes, Obesity and Metabolism*, vol. 19, no. 4, pp. 524–536, Apr. 2017, doi: 10.1111/dom.12849.

[66]

R. E. Amori, J. Lau, and A. G. Pittas, 'Efficacy and Safety of Incretin Therapy in Type 2 Diabetes', *JAMA*, vol. 298, no. 2, Jul. 2007, doi: 10.1001/jama.298.2.194.

[67]

J. B. Buse et al., 'DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks', *Diabetes Care*, vol. 33, no. 6, pp. 1255–1261, Jun. 2010, doi: 10.2337/dc09-1914.

[68]

J. B. Buse et al., 'Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes', *Annals of Internal Medicine*, vol. 154, no. 2, Jan. 2011, doi: 10.7326/0003-4819-154-2-201101180-00300.

[69]

J. B. Buse et al., 'Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)', *The Lancet*, vol. 374, no. 9683, pp. 39–47, Jul. 2009, doi: 10.1016/S0140-6736(09)60659-0.

[70]

M. A. Nauck and J. J. Meier, 'The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions', *The Lancet Diabetes & Endocrinology*, vol. 4, no. 6, pp. 525–536, Jun. 2016, doi: 10.1016/S2213-8587(15)00482-9.

[71]

S. P. Marso et al., 'Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes', *New England Journal of Medicine*, vol. 375, no. 4, pp. 311–322, Jul. 2016, doi: 10.1056/NEJMoa1603827.

[72]

'Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes', *New England Journal of*

Medicine, vol. 375, no. 18, pp. 1797–1799, Nov. 2016, doi: 10.1056/NEJMc1611289.

[73]

H. Courtney, R. Nayar, C. Rajeswaran, and R. Jandhyala, 'Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists', *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, vol. Volume 10, pp. 79–87, Mar. 2017, doi: 10.2147/DMSO.S126763.

[74]

M. E. Rotz, V. S. Ganetsky, S. Sen, and T. F. Thomas, 'Implications of incretin-based therapies on cardiovascular disease', *International Journal of Clinical Practice*, vol. 69, no. 5, pp. 531–549, May 2015, doi: 10.1111/ijcp.12572.

[75]

P. A. Levin, H. Nguyen, E. Wittbrodt, and S. C. Kim, 'Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research', *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, vol. Volume 10, pp. 123–139, Apr. 2017, doi: 10.2147/DMSO.S130834.

[76]

M. C. Riddle et al., 'Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)', *Diabetes Care*, vol. 36, no. 9, pp. 2489–2496, Sep. 2013, doi: 10.2337/dc12-2454.

[77]

K. M. Dungan et al., 'Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial', *The Lancet*, vol. 384, no. 9951, pp. 1349–1357, Oct. 2014, doi: 10.1016/S0140-6736(14)60976-4.

[78]

M. Nauck, R. S. Weinstock, G. E. Umpierrez, B. Guerci, Z. Skrivanek, and Z. Milicevic,

'Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)', *Diabetes Care*, vol. 37, no. 8, pp. 2149–2158, Aug. 2014, doi: 10.2337/dc13-2761.

[79]

'Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials-ClinicalKey'. [Online]. Available: <https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858717301043?returnurl=null&referrer=null>

[80]

'Safety and insulin: Implementation of national guidance at a local level | Journal Content | Diabetesonthenet.com'. [Online]. Available: <http://www.diabetesonthenet.com/journal-content/view/safety-and-insulin-implementation-of-national-guidance-at-a-local-level>

[81]

M. Davies, D. Dahl, T. Heise, J. Kiljanski, and C. Mathieu, 'Introduction of biosimilar insulins in Europe', *Diabetic Medicine*, vol. 34, no. 10, pp. 1340–1353, Oct. 2017, doi: 10.1111/dme.13400.

[82]

W. Crasto, J. Jarvis, and M. J. Davies, *Handbook of insulin therapies*. Switzerland: Adis, 2016 [Online]. Available: http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745

[83]

'Standards of Medical Care in Diabetes--2015: Summary of Revisions', *Diabetes Care*, vol. 38, no. Supplement_1, pp. S4–S4, Jan. 2015, doi: 10.2337/dc15-S003.

[84]

'Minimizing Hypoglycemia in Diabetes: Table 1', *Diabetes Care*, vol. 38, no. 8, pp. 1583–1591, Aug. 2015, doi: 10.2337/dc15-0279.

[85]

J. Grammes, W. Stock, C. G. Mann, E. M. Flynn, and T. Kubiak, 'Focus group study to identify the central facets of fear of hypoglycaemia in people with Type 2 diabetes mellitus', *Diabetic Medicine*, Aug. 2017, doi: 10.1111/dme.13506.

[86]

C. Carver, 'Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes', *The Diabetes Educator*, vol. 32, no. 6, pp. 910–917, Nov. 2006, doi: 10.1177/0145721706294259.

[87]

S. Mäkimattila, K. Nikkilä, and H. Yki-Järvinen, 'Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus', *Diabetologia*, vol. 42, no. 4, pp. 406–412, Mar. 1999, doi: 10.1007/s001250051172.

[88]

M. Villani, B. de Courten, and S. Zoungas, 'Emergency treatment of hypoglycaemia: a guideline and evidence review', *Diabetic Medicine*, vol. 34, no. 9, pp. 1205–1211, Sep. 2017, doi: 10.1111/dme.13379.

[89]

R. K. Simmons et al., 'A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study', *Health Technology Assessment*, vol. 20, no. 64, pp. 1–86, Aug. 2016, doi: 10.3310/hta20640.

[90]

Kamlesh Khunti, 'Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes', *PLoS ONE*, vol.

10, no. 9, 2015, doi: doi: 10.1371/journal.pone.0135702. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556656/?report=classic>

[91]

L. Tao et al., 'Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial', *Diabetic Medicine*, vol. 32, no. 7, pp. 907–919, Jul. 2015, doi: 10.1111/dme.12711.

[92]

L. J. Gray, K. Khunti, E. G. Wilmot, T. Yates, and M. J. Davies, 'External validation of two diabetes risk scores in a young UK South Asian population', *Diabetes Research and Clinical Practice*, vol. 104, no. 3, pp. 451–458, Jun. 2014, doi: 10.1016/j.diabres.2014.03.018.

[93]

L. J. Gray et al., 'Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance', *Diabetologia*, vol. 55, no. 12, pp. 3238–3244, Dec. 2012, doi: 10.1007/s00125-012-2725-8.

[94]

B. C. Johnston et al., 'Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults', *JAMA*, vol. 312, no. 9, Sep. 2014, doi: 10.1001/jama.2014.10397.

[95]

S. Steven et al., 'Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders', *Diabetes Care*, vol. 39, no. 5, pp. 808–815, May 2016, doi: 10.2337/dc15-1942.

[96]

S. Steven and R. Taylor, 'Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes', *Diabetic Medicine*, vol. 32, no. 9, pp.

1149–1155, Sep. 2015, doi: 10.1111/dme.12722.

[97]

S. J. Persaud and P. M. Jones, 'A Wake-up Call for Type 2 Diabetes?', *New England Journal of Medicine*, vol. 375, no. 11, pp. 1090–1092, Sep. 2016, doi: 10.1056/NEJMcibr1607950.

[98]

K. K. Dhatariya, C. Skedgel, and R. Fordham, 'The cost of treating diabetic ketoacidosis in the UK: a national survey of hospital resource use', *Diabetic Medicine*, vol. 34, no. 10, pp. 1361–1366, Oct. 2017, doi: 10.1111/dme.13427.

[99]

W. Crasto, J. Jarvis, and M. J. Davies, *Handbook of insulin therapies*. Switzerland: Adis, 2016 [Online]. Available: http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745

[100]

M. J. Davies et al., 'Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial', *BMJ*, vol. 336, no. 7642, pp. 491–495, Mar. 2008, doi: 10.1136/bmj.39474.922025.BE.

[101]

B. Gallwitz et al., '2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial', *The Lancet*, vol. 380, no. 9840, pp. 475–483, Aug. 2012, doi: 10.1016/S0140-6736(12)60691-6.

[102]

M. Diamant et al., 'Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial', *The Lancet*

, vol. 375, no. 9733, pp. 2234–2243, Jun. 2010, doi: 10.1016/S0140-6736(10)60406-0.

[103]

S. P. Marso et al., 'Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes', *New England Journal of Medicine*, vol. 375, no. 4, pp. 311–322, Jul. 2016, doi: 10.1056/NEJMoa1603827.

[104]

C. Wanner et al., 'Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes', *New England Journal of Medicine*, vol. 375, no. 4, pp. 323–334, Jul. 2016, doi: 10.1056/NEJMoa1515920.

[105]

'Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes', *New England Journal of Medicine*, vol. 375, no. 18, pp. 1799–1802, Nov. 2016, doi: 10.1056/NEJMc1611290.

[106]

M. A. Bethel et al., 'Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS)', *Diabetes Care*, Jan. 2017, doi: 10.2337/dc16-1135.

[107]

Merlin C. Thomas, 'Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment', *Diabetes Therapy*, vol. 7, no. 3, 2016, doi: doi: 10.1007/s13300-016-0189-4. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014795/>

[108]

Paul Craddy, 'Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison', *Diabetes Therapy*, vol. 5, no. 1, 2014, doi: doi: 10.1007/s13300-014-0061-3. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065303/>

[109]

W. L. Bennett et al., 'Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations', *Annals of Internal Medicine*, vol. 154, no. 9, May 2011, doi: 10.7326/0003-4819-154-9-201105030-00336.

[110]

J. B. Green et al., 'Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes', *New England Journal of Medicine*, vol. 373, no. 3, pp. 232–242, Jul. 2015, doi: 10.1056/NEJMoa1501352.

[111]

S. H. Min, J.-H. Yoon, S. Hahn, and Y. M. Cho, 'Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis', *Diabetes/Metabolism Research and Reviews*, vol. 33, no. 1, Jan. 2017, doi: 10.1002/dmrr.2818.

[112]

M. Capehorn et al., 'Challenges faced by physicians when discussing the Type 2 diabetes diagnosis with patients: insights from a cross-national study (IntroDia)', *Diabetic Medicine*, Mar. 2017, doi: 10.1111/dme.13357.

[113]

C. F. Deacon and H. E. Lebovitz, 'Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas', *Diabetes, Obesity and Metabolism*, vol. 18, no. 4, pp. 333–347, Apr. 2016, doi: 10.1111/dom.12610.

[114]

B. M. Mishriky, D. M. Cummings, and R. J. Tanenberg, 'The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis', *Diabetes Research and Clinical Practice*, vol. 109, no. 2, pp. 378–388, Aug. 2015, doi: 10.1016/j.diabres.2015.05.025.

[115]

H. Daly et al., 'Development of a self-management education module for those with type 2 diabetes on injectable therapies', *Practical Diabetes*, vol. 32, no. 8, pp. 305–310a, Oct. 2015, doi: 10.1002/pdi.1979.

[116]

M. Nauck, 'Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors', *Diabetes, Obesity and Metabolism*, vol. 18, no. 3, pp. 203–216, Mar. 2016, doi: 10.1111/dom.12591.

[117]

C. S. S. Frandsen and S. Madsbad, 'Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review', *Diabetic Medicine*, vol. 31, no. 11, pp. 1293–1300, Nov. 2014, doi: 10.1111/dme.12561.

[118]

M. Hadjiconstantinou et al., 'Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis', *Journal of Medical Internet Research*, vol. 18, no. 10, Oct. 2016, doi: 10.2196/jmir.5991.

[119]

D. Young-Hyman, M. de Groot, F. Hill-Briggs, J. S. Gonzalez, K. Hood, and M. Peyrot, 'Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. *Diabetes Care* 2016;39:2126–2140', *Diabetes Care*, vol. 40, no. 2, p. 287.1–287, Feb. 2017, doi: 10.2337/dc17-er02.

[120]

M. Tanner, 'Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia', *Annals of Internal Medicine*, vol. 165, no. 4, Aug. 2016, doi: 10.7326/ACPJC-2016-165-4-020.

[121]

B. M. Mishriky, D. M. Cummings, and R. J. Tanenberg, 'The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis', *Diabetes Research and Clinical Practice*, vol. 109, no. 2, pp. 378–388, Aug. 2015, doi: 10.1016/j.diabres.2015.05.025.

[122]

C. J. Bailey, J. L. Gross, A. Pieters, A. Bastien, and J. F. List, 'Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial', *The Lancet*, vol. 375, no. 9733, pp. 2223–2233, Jun. 2010, doi: 10.1016/S0140-6736(10)60407-2.

[123]

M. A. Nauck, G. Meininger, D. Sheng, L. Terranella, and P. P. Stein, 'Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial', *Diabetes, Obesity and Metabolism*, vol. 9, no. 2, pp. 194–205, Mar. 2007, doi: 10.1111/j.1463-1326.2006.00704.x.

[124]

S. P. Marso et al., 'Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes', *New England Journal of Medicine*, vol. 375, no. 19, pp. 1834–1844, Nov. 2016, doi: 10.1056/NEJMoa1607141.

[125]

B. Anderson, M. Funnell, and American Diabetes Association, *The art of empowerment: stories and strategies for diabetes educators*, 2nd ed. Alexandria, Va: American Diabetes Association, 2005.

[126]

W. Crasto, J. Jarvis, and M. J. Davies, *Handbook of insulin therapies*. Switzerland: Adis, 2016 [Online]. Available: http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745

[127]

P. R. Schauer et al., 'Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes', *New England Journal of Medicine*, vol. 366, no. 17, pp. 1567–1576, Apr. 2012, doi: 10.1056/NEJMoa1200225.

[128]

D. R. Leff and D. Heath, 'Surgery for obesity in adulthood', *BMJ*, vol. 339, no. sep22 1, pp. b3402–b3402, Sep. 2009, doi: 10.1136/bmj.b3402.

[129]

L. Sjöström et al., 'Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery', *New England Journal of Medicine*, vol. 351, no. 26, pp. 2683–2693, Dec. 2004, doi: 10.1056/NEJMoa035622.

[130]

P. R. Schauer et al., 'Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes', *New England Journal of Medicine*, vol. 376, no. 7, pp. 641–651, Feb. 2017, doi: 10.1056/NEJMoa1600869.

[131]

P. R. Schauer et al., 'Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes', *New England Journal of Medicine*, vol. 366, no. 17, pp. 1567–1576, Apr. 2012, doi: 10.1056/NEJMoa1200225.

[132]

J. Brown et al., 'Lifestyle interventions for the treatment of women with gestational diabetes', in *Cochrane Database of Systematic Reviews*, Chichester, UK: John Wiley & Sons, Ltd, 1996 [Online]. Available: <http://doi.wiley.com/10.1002/14651858.CD011970.pub2>

[133]

Kenneth Hodson, 'Gestational diabetes: emerging concepts in pathophysiology', *Obstetric Medicine*, vol. 3, no. 4, 2010, doi: doi: 10.1258/om.2010.100025. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989628/?report=classic>

[134]

Latika Sahu, 'Comparison of the American Diabetes Association and World Health Organization criteria for gestational diabetes mellitus and the outcomes of pregnancy', *Obstetric Medicine*, vol. 2, no. 4, 2009, doi: doi: 10.1258/om.2009.080049. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989660/?report=classic>

[135]

C. Moreno-Castilla, D. Mauricio, and M. Hernandez, 'Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus', *Current Diabetes Reports*, vol. 16, no. 4, Apr. 2016, doi: 10.1007/s11892-016-0717-7.

[136]

'Postnatal testing following gestational diabetes- ClinicalKey'. [Online]. Available: <https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858715003228?returnurl=null&referrer=null>

[137]

K. I. Birkeland, 'Hyperglycaemia in pregnancy: still a lot to learn', *The Lancet Diabetes & Endocrinology*, vol. 3, no. 10, pp. 752-753, Oct. 2015, doi: 10.1016/S2213-8587(15)00282-X.

[138]

Rinki Murphy, 'Monogenic diabetes and pregnancy', *Obstetric Medicine*, vol. 8, no. 3, 2015, doi: doi: 10.1177/1753495X15590713. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935018/>

[139]

Z. A. Stewart et al., 'Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes', *New England Journal of Medicine*, vol. 375, no. 7, pp. 644-654, Aug. 2016, doi:

10.1056/NEJMoa1602494.

[140]

J. S. Yeh, R. F. Kushner, and G. D. Schiff, 'Obesity and Management of Weight Loss', *New England Journal of Medicine*, vol. 375, no. 12, pp. 1187–1189, Sep. 2016, doi: 10.1056/NEJMclde1515935.

[141]

'Unit 3 – Special care groups: A practical guide to pregnancy complicated by diabetes - Diabetes & Primary Care'. [Online]. Available: <http://www.diabetesandprimarycare.co.uk/journal-content/view/unit-3-special-care-groups-a-practical-guide-to-pregnancy-complicated-by-diabetes/?preview>

[142]

Henson, Joseph, 'Associations of Sedentary Time with Fat Distribution in a High-Risk Population.', Nov. 2014 [Online]. Available: <https://lra.le.ac.uk/handle/2381/32505>

[143]

W. Crasto, J. Jarvis, and M. J. Davies, *Handbook of insulin therapies*. Switzerland: Adis, 2016 [Online]. Available: http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745

[144]

P. Srinivasan, G. C. Huang, S. A. Amiel, and N. D. Heaton, 'Islet cell transplantation', *Postgraduate Medical Journal*, vol. 83, no. 978, pp. 224–229, Apr. 2007, doi: 10.1136/pgmj.2006.053447.

[145]

P. Choudhary, N. R. Parrott, L. Birtles, and M. K. Rutter, 'Islet cell transplantation: current status in the UK (2012)', *Practical Diabetes*, vol. 29, no. 7, pp. 280–285, Sep. 2012, doi: 10.1002/pdi.1707.

[146]

Amy Kennedy, 'Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis', PLoS ONE, vol. 8, no. 3, 2013, doi: doi: 10.1371/journal.pone.0058861. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598953/>

[147]

M. Chimen, A. Kennedy, K. Nirantharakumar, T. T. Pang, R. Andrews, and P. Narendran, 'What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review', Diabetologia, vol. 55, no. 3, pp. 542–551, Mar. 2012, doi: 10.1007/s00125-011-2403-2.

[148]

D. Umpierre, 'Physical Activity Advice Only or Structured Exercise Training and Association With HbA_{1c} Levels in Type 2 Diabetes', JAMA, vol. 305, no. 17, May 2011, doi: 10.1001/jama.2011.576.

[149]

L. Avery, D. Flynn, A. van Wersch, F. F. Sniehotta, and M. I. Trenell, 'Changing Physical Activity Behavior in Type 2 Diabetes: A systematic review and meta-analysis of behavioral interventions', Diabetes Care, vol. 35, no. 12, pp. 2681–2689, Dec. 2012, doi: 10.2337/dc11-2452.

[150]

V. W. Barry, M. Baruth, M. W. Beets, J. L. Durstine, J. Liu, and S. N. Blair, 'Fitness vs. Fatness on All-Cause Mortality: A Meta-Analysis', Progress in Cardiovascular Diseases, vol. 56, no. 4, pp. 382–390, Jan. 2014, doi: 10.1016/j.pcad.2013.09.002.

[151]

L. Qin, M. J. Knol, E. Corpeleijn, and R. P. Stolk, 'Does physical activity modify the risk of obesity for type 2 diabetes: a review of epidemiological data', European Journal of Epidemiology, vol. 25, no. 1, pp. 5–12, Jan. 2010, doi: 10.1007/s10654-009-9395-y.

[152]

I.-M. Lee, 'Physical Activity and Weight Gain Prevention', *JAMA*, vol. 303, no. 12, Mar. 2010, doi: 10.1001/jama.2010.312.

[153]

John M Jakicic, 'Physical activity considerations for the treatment and prevention of obesity', *The American Journal of Clinical Nutrition*, vol. 82, no. 1, pp. 226S-229S, Jan. 2005 [Online]. Available: <http://ajcn.nutrition.org/content/82/1/226S>

[154]

I. Heinonen et al., 'Sedentary behaviours and obesity in adults: the Cardiovascular Risk in Young Finns Study', *BMJ Open*, vol. 3, no. 6, May 2013, doi: 10.1136/bmjopen-2013-002901.

[155]

J. F. Sallis et al., 'Progress in physical activity over the Olympic quadrennium', *The Lancet*, vol. 388, no. 10051, pp. 1325-1336, Sep. 2016, doi: 10.1016/S0140-6736(16)30581-5.

[156]

Y. A. W. Hartman, H. J. Jansen, M. T. E. Hopman, C. J. Tack, and D. H. J. Thijssen, 'Insulin-Associated Weight Gain in Type 2 Diabetes Is Associated With Increases in Sedentary Behavior', *Diabetes Care*, vol. 40, no. 9, pp. e120-e121, Sep. 2017, doi: 10.2337/dc17-0787.

[157]

Michael Riddell, 'Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the Role for Continuous Glucose Monitoring', *Journal of diabetes science and technology (Online)*, vol. 3, no. 4, 2009, doi: 10.1177/193229680900300439. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769951/>